Adolescent Obesity Drugs: 2026 Review

A September 2026 evidence review of obesity medicines for adolescents found one clear result and one large gap. Semaglutide has the strongest published weight evidence in this age group, led by a 16.1% mean reduction in body mass index at 68 weeks in STEP TEENS. The review found far less adolescent obesity evidence for newer medicines such as tirzepatide and CagriSema.^[1] This is a review of existing trials, not a new randomized trial, and its conclusions should be read with that distinction in mind.

The number comes from STEP TEENS

The review searched PubMed and Scopus for randomized trials and meta-analyses lasting more than 12 weeks in patients aged 12 to 18. Its main semaglutide figure comes from STEP TEENS, a randomized, double-blind trial that enrolled 201 adolescents with obesity, or overweight plus at least one weight-related condition. Participants were assigned semaglutide or placebo for 68 weeks, with lifestyle intervention in both groups.^[2] The trial administered a weekly study dose under a protocol. That is a report of trial design, not a recommendation for an individual patient.

At week 68, mean BMI had fallen 16.1% in the semaglutide group and risen 0.6% in the placebo group, an estimated difference of 16.7 percentage points. Seventy-three percent of semaglutide participants lost at least 5% of body weight, compared with 18% on placebo.^[2] Those are group averages from a controlled trial. They do not predict one teenager's response, and they do not show how outcomes hold up over many years.

The current US prescribing information reflects the resulting pediatric indication. Wegovy is indicated for long-term weight reduction in patients aged 12 years and older with obesity.^[3] Approval tells us that regulators judged the submitted evidence for that defined use. It does not turn treatment into a one-size-fits-all choice, particularly for a growing adolescent with other medicines or health conditions.

The safety result needs equal billing

The efficacy headline is only half of the readout. Gastrointestinal adverse events occurred in 62% of participants assigned semaglutide and 42% assigned placebo. Five of 133 semaglutide participants developed cholelithiasis, commonly called gallstones, while none of the 67 placebo participants did. Serious adverse events were reported in 11% and 9% of the groups, respectively.^[2] The FDA-approved label separately lists the pediatric gastrointestinal pattern, including nausea, vomiting, and diarrhea.^[3]

The 2026 review says no short-term safety problem has changed the overall evidence picture, but it also calls for longer follow-up and pediatric safety trials.^[1] Both statements can be true. A trial can support an approval while leaving uncertainty about treatment through later adolescence, transition into adulthood, growth, adherence, and outcomes after discontinuation.

Completion also matters when interpreting the result. Of 201 randomized participants, 180 completed treatment, which the trial reports as 90%.^[2] That is a high completion rate for the 68-week protocol, but it does not remove the need to understand why some participants stopped or how persistence looks outside a trial. Scheduled visits, eligibility rules, and study support can differ from routine clinical care. The label and trial publication describe observed risks; neither can decide the benefit-risk balance for a particular teenager without clinical assessment.

Tirzepatide remains a different question

Adult results cannot simply be copied into adolescent obesity care. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates two hormone receptors involved in glucose control and appetite. The review identifies tirzepatide as a forthcoming option but says adolescent evidence remains limited compared with adult evidence.^[1] Readers can find the adult evidence and approval context on our tirzepatide evidence page, but those data do not answer the pediatric obesity question.

This distinction is especially easy to miss because tirzepatide has pediatric data in type 2 diabetes. A medicine studied in young people for one condition is not automatically proven for another condition. Obesity trials may use different entry criteria, endpoints, follow-up periods, and background care. The review therefore treats tirzepatide and CagriSema as evidence gaps rather than substitutes for the semaglutide trial record.^[1]

What this review cannot settle

The paper is a focused minireview, not a new trial and not a formal clinical guideline. Its search concentrated on trials and meta-analyses lasting more than 12 weeks, and its conclusions depend on the quality and duration of the studies already available.^[1] That makes it useful for mapping the field, but it cannot provide a head-to-head answer for every medicine or measure rare harms that need much larger populations and longer observation.

Access is another limit. The authors flag cost and social inequality as barriers that can separate trial efficacy from real care.^[1] A medicine can produce a strong average result in a trial while remaining difficult to obtain, continue, or pair with specialist support. The study does not establish how those barriers differ across health systems, insurance arrangements, or countries.

Why this matters

The useful takeaway is narrower than a ranking of obesity drugs. Semaglutide has a randomized adolescent trial with a large mean BMI change, a defined adverse-event record, and a pediatric indication in the US label.^[2][3] Tirzepatide and CagriSema may attract attention because of adult findings, but the 2026 review says pediatric obesity evidence has not caught up.^[1] Families considering treatment need a clinician who can weigh the approved options against medical history, growth, tolerability, and access. This article does not provide a dosing or treatment plan.